IP Library Granted Patent US 11,472,857
Granted Patent B2
US 11,472,857 · App. 17/177,799 · Granted Oct 18, 2022

Modified glucagon molecules

Inventors: Elizabeth M. Murphy Topp (Lafayette, IN); Hamed Tabatabaei Ghomi (San Diego, CA); Markus Lill (West Lafayette, IN); Shenbaga Moorthy Balakrishnan (Virudhunagar District, IN)
Assignee: Purdue Research Foundation
C07K14/605A61K38/26A61K47/52A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,472,857
App. No.
17/177,799
Granted
Oct 18, 2022
Kind
B2
Abstract

The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation. Modifications may include, for example, phosphorylation or sulfation.

Claims (12)

1. A modified glucagon molecule that comprises one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH wherein the one or more modified amino acids comprise one or more amino acids that have been modified with a sulfate group.

2. The modified glucagon molecule according to claim 1 , wherein the one or more modified amino acids further comprise one or more phosphorylated amino acids.

3. The modified glucagon molecule according to claim 2 , wherein the glucagon molecule is doubly phosphorylated.

4. The modified glucagon molecule according to claim 2 , wherein the glucagon molecule is triply phosphorylated.

5. The modified glucagon molecule according to claim 2 , wherein the one or more phosphorylated amino acids are selected from the group consisting of His1, Ser2, Thr5, Thr7, Ser8, Tyr10, Ser11, Tyr13, Ser16, Thr29, and combinations thereof.

6. The modified glucagon molecule according to claim 5 , wherein the one or more phosphorylated amino acids are selected from the group consisting of Thr5, Ser8, Ser16 and combinations thereof.

7. A glucagon prodrug comprising one or more modified amino acids such that the glucagon prodrug is soluble at a substantially neutral pH, wherein the one or more modified amino acids comprise one or more amino acids that have been modified with a sulfate group that is cleaved upon administration of the prodrug.

8. The glucagon prodrug according to claim 7 , wherein the sulfate group is chemically or enzymatically cleaved.

9. The glucagon prodrug according to claim 7 , wherein the one or more modified amino acids further comprise one or more amino acids that have been modified with a phosphate group.

10. The glucagon prodrug according to claim 9 , wherein two or more amino acids that have been modified with a phosphate group.

11. The glucagon prodrug according to claim 9 , wherein three or more amino acids that have been modified with a phosphate group.

12. The glucagon prodrug according to claim 9 , wherein the one or more amino acids that have been modified with a phosphate group are selected from the group consisting of His1, Ser2, Thr5, Thr7, Ser8, Tyr10, Ser11, Tyr13, Ser16, Thr29, and combinations thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 2, 2023
From: PURDUE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065431/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2021
From: MURPHY TOPP, ELIZABETH M.; TABATABAEI GHOMI, HAMED; LILL, MARKUS; BALAKRISHNAN, SHENBAGA MOORTHY
To: PURDUE RESEARCH FOUNDATION
Reel/Frame 056021/0144 →
Continuity (4)
Continuation 16278851 · Feb 19, 2019
Continuation 15745483
Provisional Application 62195537 · Jul 22, 2015
Related Publication 20210300982A1 · Sep 30, 2021